AR060222A1 - Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma - Google Patents

Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma

Info

Publication number
AR060222A1
AR060222A1 ARP070101334A ARP070101334A AR060222A1 AR 060222 A1 AR060222 A1 AR 060222A1 AR P070101334 A ARP070101334 A AR P070101334A AR P070101334 A ARP070101334 A AR P070101334A AR 060222 A1 AR060222 A1 AR 060222A1
Authority
AR
Argentina
Prior art keywords
kinase
junk
treat glaucoma
inhibitors
terminal inhibitors
Prior art date
Application number
ARP070101334A
Other languages
English (en)
Spanish (es)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR060222A1 publication Critical patent/AR060222A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP070101334A 2006-03-31 2007-03-29 Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma AR060222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/394,893 US7803824B2 (en) 2004-10-29 2006-03-31 Use of inhibitors of Jun N-terminal kinases to treat glaucoma

Publications (1)

Publication Number Publication Date
AR060222A1 true AR060222A1 (es) 2008-06-04

Family

ID=38523463

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101334A AR060222A1 (es) 2006-03-31 2007-03-29 Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma

Country Status (13)

Country Link
US (3) US7803824B2 (enExample)
EP (1) EP2004158A2 (enExample)
JP (1) JP5241033B2 (enExample)
KR (1) KR20080108503A (enExample)
CN (1) CN101415407B (enExample)
AR (1) AR060222A1 (enExample)
AU (1) AU2007235111B2 (enExample)
BR (1) BRPI0710099A2 (enExample)
CA (1) CA2644721A1 (enExample)
MX (1) MX2008011319A (enExample)
TW (1) TWI419694B (enExample)
WO (1) WO2007117849A2 (enExample)
ZA (1) ZA200807667B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
US20120077753A1 (en) * 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
EA201501080A1 (ru) * 2013-06-26 2016-07-29 Ксижен Инфлемейшн Лтд. Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
EP3160489B9 (en) * 2014-06-26 2023-10-04 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040847A1 (en) * 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
CN1323208A (zh) 1998-10-13 2001-11-21 协和发酵工业株式会社 眼病治疗剂
WO2000035906A2 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
DE60041763D1 (de) 1999-04-23 2009-04-23 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
DE60039616D1 (de) 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
KR20080028516A (ko) 1999-08-19 2008-03-31 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
EP1088822A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl hydrazide derivatives
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1289523A1 (en) 2000-06-01 2003-03-12 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1193256A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
WO2002062792A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2002083648A1 (fr) 2001-04-16 2002-10-24 Eisai Co., Ltd. Nouveau compose a base de 1h-indazole
EP1426050A4 (en) 2001-08-23 2005-05-25 Takeda Pharmaceutical JNK INHIBITORS
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
JP2003129190A (ja) 2001-10-19 2003-05-08 Sumitomo Metal Ind Ltd マルテンサイト系ステンレス鋼およびその製造方法
US20030138819A1 (en) 2001-10-26 2003-07-24 Haiqing Gong Method for detecting disease
US7390797B2 (en) * 2002-02-28 2008-06-24 Eisai Co., Ltd. Fused indazole compounds
EP1497420A4 (en) * 2002-04-30 2005-04-27 Alcon Inc AGENTS THAT REGULATE, RESTRICT OR MODULATE THE ACTIVITY AND / OR EXPRESSION OF BIND WEAVE GROWTH FACTOR (CTGF) AS UNIQUE MEDICAMENTS BOTH TO REDUCE EYESPRINTS AND TREAT GLACCOMPETOSIS RETINOPATHIES / OPTIC NEUROPATHIES
US7465736B2 (en) 2002-06-14 2008-12-16 Laboratoires Serono S.A. Azole methylidene cyanide derivatives and their use as protein kinase modulators
JP2006502183A (ja) * 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
US20040092568A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US7803824B2 (en) * 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060275797A1 (en) * 2005-03-21 2006-12-07 Alcon Manufacturing, Ltd. Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Also Published As

Publication number Publication date
JP2009532373A (ja) 2009-09-10
WO2007117849A2 (en) 2007-10-18
TWI419694B (zh) 2013-12-21
MX2008011319A (es) 2008-09-19
WO2007117849A3 (en) 2008-04-10
AU2007235111B2 (en) 2012-03-22
KR20080108503A (ko) 2008-12-15
AU2007235111A1 (en) 2007-10-18
US20060172991A1 (en) 2006-08-03
BRPI0710099A2 (pt) 2011-08-02
US20100311716A1 (en) 2010-12-09
CN101415407A (zh) 2009-04-22
JP5241033B2 (ja) 2013-07-17
EP2004158A2 (en) 2008-12-24
CA2644721A1 (en) 2007-10-18
TW200744601A (en) 2007-12-16
CN101415407B (zh) 2011-05-11
ZA200807667B (en) 2010-07-28
US7803824B2 (en) 2010-09-28
US20120004274A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
NO20054951L (no) Prostaglandinanaloger som EP4-reseptorantagonister
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
UY30060A1 (es) Inhibición de la rho quinasa mediada por arni para el tratamiento de trastornos
UY29349A1 (es) Inhibicion de los objetivos de la hipertensión ocular mediada por arni
NO20074390L (no) Forsterket bimatoprost oye-opplosning
EA200970067A1 (ru) Агонисты ep2
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
NO20082125L (no) Substituerte benzokondenserte derivater og deres anvendelse som vanilloidreseptorligander
ATE432323T1 (de) Bitumenzusammensetzung
BRPI0817351A2 (pt) Composição para cuidado pessoal
PE20250666A1 (es) Combinaciones, mezclas y composiciones fungicidas y usos de las mismas
CL2021003455A1 (es) Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
MX2025002677A (es) Moduladores de la alfa-1 antitripsina
BRPI0416959A (pt) composição, artigo, e, método para conferir repelência e anti-sujeira a um substrato, tendo uma ou mais superfìcies
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
NO20063944L (no) Piperidinylkarbonyl-pyrrolidiner og deres anvendelse som melanokortinagonister
ATE451361T1 (de) Materialien und methoden zur behandlung von koagulationsstörungen
CL2008003332A1 (es) Compuestos derivados de ciclopentano sustituido, como agentes hipotensores oculares; composicion oftalmologicamente aceptable; y uso para el tratamiento del glaucoma.
TW200744601A (en) Use of inhibitors of Jun N-terminal kinases to treat glaucoma
PE20090962A1 (es) Nuevas composiciones a base de taxoides
PE20220593A1 (es) Composiciones comprimidas de macitentan, metodos y usos de las mismas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal